期刊文献+

抗sHLA-Ⅰ免疫磁珠的制备与鉴定

The Preparation and Appreciation of Anti-sHLA-I Immune Magnetic Bead
下载PDF
导出
摘要 目的制备抗sHLA-Ⅰ免疫磁珠去除红细胞悬液和机采血小板中的sHLA-Ⅰ分子。方法将单克隆抗体W6/32以共价偶联的方式包被制备免疫磁珠,以FITC标记的羊抗鼠二抗标记磁珠,用流式细胞仪鉴定包被效果。取10例红细胞悬液和机采血小板上清和制备好的免疫磁珠孵育后移去磁珠,用ELISA检测吸附前后sHLA-Ⅰ浓度变化评价吸附效果。结果制备的抗sHLA-Ⅰ免疫磁珠包被效率约为75%。对红细胞悬液和机采血小板中sHLA-Ⅰ的吸附效果可达到84%和83%。结论采用单克隆抗体W6/32制备的免疫磁珠能有效去除红细胞悬液和机采血小板中的sHLA-Ⅰ分子,在改善临床输血安全方面有广阔的应用前景。 Objective To prepare anti-soluble human leukocyte antigens Ⅰ ( sHLA-Ⅰ ) immune magnetic bead for adsorbing and removing the soluble HLA - Ⅰ of red cell suspension and machine adopting platelet. Methods The magnetic beads are coated with monoclonal antibody W6/32 by covalence coupling' s way. Then the magnetic beads are marked by the sheep-anti-mouse second antibody marked by FITC and are appraised the coating effect by flow eytometer ( FCM ). Ten example red ceil suspension and machine adopting platelet supernatant are selected and incubated with the prepared immune magnetic bead. Then the beads are removed from the mixed liquor and the density of the sHLA-Ⅰ in the ,mpernatant is detected by ELISA to compare the density change heft)re and after adsorbing and appreciate the adsorbing effects. Results The prepared anti-sHLA-Ⅰ magnetic beads' coating efficiency is 75%. The adsorbing effect to soluble HLA-Ⅰ existing in red cell suspension and machine adopting platelet respectively is 84% and 83%. Conclusion The magnetic beads prepared with monoclonal antibody W6/32 can adsorb and remove efficiently the soluble HLA-Ⅰ existing in red cell suspension and machine adopting platelet, which will have extensively applied perspective in improving clinical transfusing blood safe.
出处 《中国现代医生》 2011年第19期149-150,152,共3页 China Modern Doctor
关键词 可溶性组织相容性抗原Ⅰ类分子 免疫磁珠 Soluble human leukocyte antigens Ⅰ ( HLA-Ⅰ ) Immune magnetic bead
  • 相关文献

参考文献7

  • 1Ghio M, Contini P, Mazzei C, et al. Soluble HLA class I and Fas ligand molec Ix Les in blood components and their role in the immunomod ~ Latory effects of blood transfusions[J]. Leuk Lymphoma, 2000,39 ( 1-2 ) : 29-36.
  • 2Hebert PC, Fergusson D, Blajchman MA, et al. Clinical outcome following institution of the Canadian universal leukoreduction program for red blood cell transfusions[J]. JAMA,2003,289 ( 15 ): 1993-1995.
  • 3Chelemer SB, Prato BS, Cox PM Jr, et al. Association of bacterial infection and red blood cell transfusion after coronary artery bypass surgery[J]. Ann Thorac Surg,2002,73 : 138-142.
  • 4Mynster T, Nielsen HJ, Danish, et al. Storage time of transfused blood and disease recurrence after eolorectal cancer surgery[J]. Dis Colon Rectum,2001, 44: 955-964.
  • 5Ghio P, Contini C, Mazze S, et al. Soluble HLA class I, HLA class I1, and Fas ligand in blood components : A possible key to explain the Immunomod p. latory effects of altogeneic blood transfusioas[J]. Blood, 1999,93 ( 5 ) : 1770-1777.
  • 6Ottonello L, Ghio M, Contini P, et al. Nonleukoreduced red blood cell transfusion induces a sustained inhibition of neutrophil chemotaxis by stimuLating in vivo production of transforming growth factor-betal by neutrophils: role of the immunoglobuLinlike transcript 1, sFasL, and sHLA- IH1. Transfusion.2007.47 ( 8 ): 1395-1404.
  • 7Novikov VV, Egorova NI, Kumikov GY, et al.Serum levels of soluble HLA and IL-2R molecuLes in patients with urogenital chlamydia infection[J]. Adv Exp Med Biol, 2007,601: 285-289.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部